nodes	percent_of_prediction	percent_of_DWPC	metapath
Losartan—ACE—psoriasis	0.284	1	CbGaD
Losartan—UGT1A10—Mycophenolate mofetil—psoriasis	0.103	0.195	CbGbCtD
Losartan—UGT2B7—Mycophenolic acid—psoriasis	0.0441	0.0831	CbGbCtD
Losartan—UGT1A1—Mycophenolic acid—psoriasis	0.0381	0.0718	CbGbCtD
Losartan—SLCO1B3—Mycophenolate mofetil—psoriasis	0.0253	0.0477	CbGbCtD
Losartan—UGT2B7—Mycophenolate mofetil—psoriasis	0.0247	0.0464	CbGbCtD
Losartan—UGT1A1—Mycophenolate mofetil—psoriasis	0.0213	0.0401	CbGbCtD
Losartan—ALB—Acitretin—psoriasis	0.0173	0.0325	CbGbCtD
Losartan—CYP2C8—Tazarotene—psoriasis	0.0169	0.0318	CbGbCtD
Losartan—CYP3A5—Beclomethasone—psoriasis	0.0163	0.0307	CbGbCtD
Losartan—CYP1A2—Clobetasol propionate—psoriasis	0.016	0.0302	CbGbCtD
Losartan—SLCO1B1—Mycophenolate mofetil—psoriasis	0.0148	0.0278	CbGbCtD
Losartan—SLCO1B1—Cyclosporine—psoriasis	0.0112	0.0211	CbGbCtD
Losartan—SLCO1B3—Methotrexate—psoriasis	0.0102	0.0191	CbGbCtD
Losartan—CYP1A2—Methoxsalen—psoriasis	0.00842	0.0158	CbGbCtD
Losartan—ALB—Mycophenolate mofetil—psoriasis	0.00808	0.0152	CbGbCtD
Losartan—SLC2A9—skeletal joint—psoriasis	0.00762	0.64	CbGeAlD
Losartan—CYP2C8—Cholecalciferol—psoriasis	0.0072	0.0136	CbGbCtD
Losartan—SLC22A6—Cyclosporine—psoriasis	0.00719	0.0135	CbGbCtD
Losartan—CYP3A5—Mycophenolate mofetil—psoriasis	0.00649	0.0122	CbGbCtD
Losartan—ALB—Prednisone—psoriasis	0.00646	0.0122	CbGbCtD
Losartan—CYP2C8—Mycophenolate mofetil—psoriasis	0.00624	0.0118	CbGbCtD
Losartan—CYP2C19—Cholecalciferol—psoriasis	0.00604	0.0114	CbGbCtD
Losartan—SLCO1B1—Methotrexate—psoriasis	0.00592	0.0111	CbGbCtD
Losartan—CYP3A4—Calcitriol—psoriasis	0.00567	0.0107	CbGbCtD
Losartan—CYP3A5—Hydrocortisone—psoriasis	0.00521	0.00981	CbGbCtD
Losartan—CYP2C9—Cholecalciferol—psoriasis	0.00502	0.00946	CbGbCtD
Losartan—CYP2C8—Hydrocortisone—psoriasis	0.00501	0.00944	CbGbCtD
Losartan—CYP3A5—Cyclosporine—psoriasis	0.00492	0.00927	CbGbCtD
Losartan—CYP2C8—Cyclosporine—psoriasis	0.00473	0.00891	CbGbCtD
Losartan—CYP3A4—Methoxsalen—psoriasis	0.00441	0.0083	CbGbCtD
Losartan—ABCB1—Mycophenolate mofetil—psoriasis	0.00423	0.00796	CbGbCtD
Losartan—CYP2C19—Prednisone—psoriasis	0.00419	0.00789	CbGbCtD
Losartan—CYP2C19—Cyclosporine—psoriasis	0.00397	0.00748	CbGbCtD
Losartan—SLC22A6—Methotrexate—psoriasis	0.00381	0.00716	CbGbCtD
Losartan—ABCB1—Betamethasone—psoriasis	0.00363	0.00683	CbGbCtD
Losartan—ABCB1—Prednisolone—psoriasis	0.00358	0.00674	CbGbCtD
Losartan—ABCB1—Hydrocortisone—psoriasis	0.00339	0.00639	CbGbCtD
Losartan—ABCB1—Prednisone—psoriasis	0.00338	0.00636	CbGbCtD
Losartan—CYP2C9—Cyclosporine—psoriasis	0.0033	0.00622	CbGbCtD
Losartan—CYP3A5—Dexamethasone—psoriasis	0.00324	0.0061	CbGbCtD
Losartan—ALB—Methotrexate—psoriasis	0.00324	0.0061	CbGbCtD
Losartan—ABCB1—Cyclosporine—psoriasis	0.0032	0.00603	CbGbCtD
Losartan—CYP2C8—Dexamethasone—psoriasis	0.00312	0.00587	CbGbCtD
Losartan—CYP3A4—Cholecalciferol—psoriasis	0.00292	0.0055	CbGbCtD
Losartan—CYP2C19—Dexamethasone—psoriasis	0.00261	0.00492	CbGbCtD
Losartan—CYP3A4—Mycophenolate mofetil—psoriasis	0.00253	0.00477	CbGbCtD
Losartan—CYP3A4—Triamcinolone—psoriasis	0.00253	0.00477	CbGbCtD
Losartan—CYP2C9—Dexamethasone—psoriasis	0.00217	0.00409	CbGbCtD
Losartan—CYP3A4—Betamethasone—psoriasis	0.00217	0.00409	CbGbCtD
Losartan—ACE—skeletal joint—psoriasis	0.00216	0.181	CbGeAlD
Losartan—CYP3A4—Prednisolone—psoriasis	0.00214	0.00404	CbGbCtD
Losartan—ABCB1—Dexamethasone—psoriasis	0.00211	0.00397	CbGbCtD
Losartan—CYP3A4—Hydrocortisone—psoriasis	0.00203	0.00383	CbGbCtD
Losartan—CYP3A4—Prednisone—psoriasis	0.00202	0.00381	CbGbCtD
Losartan—CYP3A4—Cyclosporine—psoriasis	0.00192	0.00361	CbGbCtD
Losartan—Irbesartan—JUN—psoriasis	0.00171	0.674	CrCbGaD
Losartan—ABCB1—Methotrexate—psoriasis	0.0017	0.00319	CbGbCtD
Losartan—CYP3A4—Dexamethasone—psoriasis	0.00126	0.00238	CbGbCtD
Losartan—AGTR1—endothelium—psoriasis	0.00103	0.0867	CbGeAlD
Losartan—Telmisartan—PPARG—psoriasis	0.00083	0.326	CrCbGaD
Losartan—ACE—endothelium—psoriasis	0.000762	0.064	CbGeAlD
Losartan—AGTR1—tendon—psoriasis	0.000336	0.0282	CbGeAlD
Losartan—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	9.3e-05	0.00259	CbGpPWpGaD
Losartan—SLCO1B3—SLC-mediated transmembrane transport—CP—psoriasis	9.23e-05	0.00258	CbGpPWpGaD
Losartan—ALB—Lipoprotein metabolism—APOE—psoriasis	9.09e-05	0.00254	CbGpPWpGaD
Losartan—UGT2B17—Metabolism—CARM1—psoriasis	9.04e-05	0.00252	CbGpPWpGaD
Losartan—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	9e-05	0.00251	CbGpPWpGaD
Losartan—AGTR1—Allograft Rejection—IFNG—psoriasis	8.94e-05	0.00249	CbGpPWpGaD
Losartan—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	8.81e-05	0.00246	CbGpPWpGaD
Losartan—CYP2C19—Biological oxidations—CYP2S1—psoriasis	8.65e-05	0.00241	CbGpPWpGaD
Losartan—ACE—Metabolism of proteins—REN—psoriasis	8.61e-05	0.0024	CbGpPWpGaD
Losartan—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	8.53e-05	0.00238	CbGpPWpGaD
Losartan—AGTR1—GPCR downstream signaling—HCAR2—psoriasis	8.48e-05	0.00237	CbGpPWpGaD
Losartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	8.41e-05	0.00235	CbGpPWpGaD
Losartan—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	8.38e-05	0.00234	CbGpPWpGaD
Losartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—psoriasis	8.34e-05	0.00233	CbGpPWpGaD
Losartan—AGTR1—Allograft Rejection—CXCL8—psoriasis	8.31e-05	0.00232	CbGpPWpGaD
Losartan—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	8.26e-05	0.0023	CbGpPWpGaD
Losartan—CYP2C9—Biological oxidations—CYP2S1—psoriasis	7.88e-05	0.0022	CbGpPWpGaD
Losartan—AGTR1—GPCR ligand binding—CCL20—psoriasis	7.79e-05	0.00217	CbGpPWpGaD
Losartan—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	7.78e-05	0.00217	CbGpPWpGaD
Losartan—AGTR1—Signaling by GPCR—HCAR2—psoriasis	7.7e-05	0.00215	CbGpPWpGaD
Losartan—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	7.67e-05	0.00214	CbGpPWpGaD
Losartan—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	7.62e-05	0.00213	CbGpPWpGaD
Losartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	7.51e-05	0.0021	CbGpPWpGaD
Losartan—ALB—Hemostasis—SERPINB8—psoriasis	7.41e-05	0.00207	CbGpPWpGaD
Losartan—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	7.19e-05	0.00201	CbGpPWpGaD
Losartan—ABCB1—Allograft Rejection—HLA-C—psoriasis	7.17e-05	0.002	CbGpPWpGaD
Losartan—ABCB1—Allograft Rejection—IL13—psoriasis	7.13e-05	0.00199	CbGpPWpGaD
Losartan—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—psoriasis	7.08e-05	0.00198	CbGpPWpGaD
Losartan—SLC22A6—SLC-mediated transmembrane transport—CP—psoriasis	6.82e-05	0.0019	CbGpPWpGaD
Losartan—AGTR1—Allograft Rejection—VEGFA—psoriasis	6.75e-05	0.00188	CbGpPWpGaD
Losartan—CYP1A2—Biological oxidations—CYP2S1—psoriasis	6.74e-05	0.00188	CbGpPWpGaD
Losartan—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	6.64e-05	0.00185	CbGpPWpGaD
Losartan—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	6.63e-05	0.00185	CbGpPWpGaD
Losartan—ABCB1—Allograft Rejection—IL17A—psoriasis	6.56e-05	0.00183	CbGpPWpGaD
Losartan—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	6.53e-05	0.00182	CbGpPWpGaD
Losartan—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.28e-05	0.00175	CbGpPWpGaD
Losartan—ALB—Folate Metabolism—CAT—psoriasis	6.22e-05	0.00174	CbGpPWpGaD
Losartan—SLCO1B1—SLC-mediated transmembrane transport—CP—psoriasis	6.2e-05	0.00173	CbGpPWpGaD
Losartan—ABCB1—Allograft Rejection—IL12B—psoriasis	6.1e-05	0.0017	CbGpPWpGaD
Losartan—ALB—Vitamin B12 Metabolism—CRP—psoriasis	6.07e-05	0.0017	CbGpPWpGaD
Losartan—ALB—Lipid and lipoprotein metabolism—APOE—psoriasis	6.04e-05	0.00169	CbGpPWpGaD
Losartan—ABCB1—Allograft Rejection—HLA-E—psoriasis	5.95e-05	0.00166	CbGpPWpGaD
Losartan—ALB—Vitamin B12 Metabolism—APOE—psoriasis	5.94e-05	0.00166	CbGpPWpGaD
Losartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.86e-05	0.00164	CbGpPWpGaD
Losartan—CYP1A2—Tryptophan metabolism—CAT—psoriasis	5.81e-05	0.00162	CbGpPWpGaD
Losartan—AGTR1—Allograft Rejection—TNF—psoriasis	5.78e-05	0.00161	CbGpPWpGaD
Losartan—ALB—Folate Metabolism—IL4—psoriasis	5.72e-05	0.0016	CbGpPWpGaD
Losartan—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	5.7e-05	0.00159	CbGpPWpGaD
Losartan—ALB—Vitamin B12 Metabolism—ICAM1—psoriasis	5.58e-05	0.00156	CbGpPWpGaD
Losartan—UGT2B17—Metabolism—CAT—psoriasis	5.56e-05	0.00155	CbGpPWpGaD
Losartan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	5.55e-05	0.00155	CbGpPWpGaD
Losartan—UGT1A3—Metabolism—NDUFA5—psoriasis	5.35e-05	0.00149	CbGpPWpGaD
Losartan—Tachycardia—Triamcinolone—psoriasis	5.31e-05	0.000394	CcSEcCtD
Losartan—Erythema—Prednisone—psoriasis	5.27e-05	0.00039	CcSEcCtD
Losartan—Musculoskeletal discomfort—Hydrocortisone—psoriasis	5.27e-05	0.00039	CcSEcCtD
Losartan—Hyperhidrosis—Triamcinolone—psoriasis	5.26e-05	0.00039	CcSEcCtD
Losartan—Agranulocytosis—Methotrexate—psoriasis	5.26e-05	0.00039	CcSEcCtD
Losartan—Feeling abnormal—Mycophenolate mofetil—psoriasis	5.23e-05	0.000387	CcSEcCtD
Losartan—Insomnia—Hydrocortisone—psoriasis	5.23e-05	0.000387	CcSEcCtD
Losartan—CYP3A4—Biological oxidations—CYP2S1—psoriasis	5.2e-05	0.00145	CbGpPWpGaD
Losartan—Paraesthesia—Hydrocortisone—psoriasis	5.19e-05	0.000385	CcSEcCtD
Losartan—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	5.19e-05	0.000384	CcSEcCtD
Losartan—Urticaria—Cyclosporine—psoriasis	5.17e-05	0.000383	CcSEcCtD
Losartan—Myalgia—Dexamethasone—psoriasis	5.15e-05	0.000382	CcSEcCtD
Losartan—Myalgia—Betamethasone—psoriasis	5.15e-05	0.000382	CcSEcCtD
Losartan—Body temperature increased—Cyclosporine—psoriasis	5.14e-05	0.000381	CcSEcCtD
Losartan—Abdominal pain—Cyclosporine—psoriasis	5.14e-05	0.000381	CcSEcCtD
Losartan—Anxiety—Dexamethasone—psoriasis	5.13e-05	0.00038	CcSEcCtD
Losartan—Anxiety—Betamethasone—psoriasis	5.13e-05	0.00038	CcSEcCtD
Losartan—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	5.13e-05	0.00143	CbGpPWpGaD
Losartan—Vomiting—Mycophenolic acid—psoriasis	5.11e-05	0.000379	CcSEcCtD
Losartan—Discomfort—Dexamethasone—psoriasis	5.09e-05	0.000377	CcSEcCtD
Losartan—Discomfort—Betamethasone—psoriasis	5.09e-05	0.000377	CcSEcCtD
Losartan—Dyspepsia—Hydrocortisone—psoriasis	5.09e-05	0.000377	CcSEcCtD
Losartan—Rash—Mycophenolic acid—psoriasis	5.07e-05	0.000376	CcSEcCtD
Losartan—Dermatitis—Mycophenolic acid—psoriasis	5.06e-05	0.000375	CcSEcCtD
Losartan—Pain—Prednisolone—psoriasis	5.06e-05	0.000375	CcSEcCtD
Losartan—Hepatitis—Methotrexate—psoriasis	5.06e-05	0.000375	CcSEcCtD
Losartan—SLCO1B3—Metabolism—NDUFA5—psoriasis	5.05e-05	0.00141	CbGpPWpGaD
Losartan—Urticaria—Mycophenolate mofetil—psoriasis	5.04e-05	0.000373	CcSEcCtD
Losartan—Headache—Mycophenolic acid—psoriasis	5.04e-05	0.000373	CcSEcCtD
Losartan—Decreased appetite—Hydrocortisone—psoriasis	5.02e-05	0.000372	CcSEcCtD
Losartan—Pharyngitis—Methotrexate—psoriasis	5.02e-05	0.000372	CcSEcCtD
Losartan—Abdominal pain—Mycophenolate mofetil—psoriasis	5.01e-05	0.000372	CcSEcCtD
Losartan—Body temperature increased—Mycophenolate mofetil—psoriasis	5.01e-05	0.000372	CcSEcCtD
Losartan—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.01e-05	0.0014	CbGpPWpGaD
Losartan—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	4.99e-05	0.00139	CbGpPWpGaD
Losartan—Fatigue—Hydrocortisone—psoriasis	4.98e-05	0.000369	CcSEcCtD
Losartan—Vision blurred—Prednisone—psoriasis	4.97e-05	0.000368	CcSEcCtD
Losartan—Musculoskeletal discomfort—Triamcinolone—psoriasis	4.96e-05	0.000367	CcSEcCtD
Losartan—ALB—Selenium Micronutrient Network—CAT—psoriasis	4.95e-05	0.00138	CbGpPWpGaD
Losartan—ALB—Folate Metabolism—CRP—psoriasis	4.94e-05	0.00138	CbGpPWpGaD
Losartan—Pain—Hydrocortisone—psoriasis	4.94e-05	0.000366	CcSEcCtD
Losartan—Anaphylactic shock—Dexamethasone—psoriasis	4.94e-05	0.000366	CcSEcCtD
Losartan—Anaphylactic shock—Betamethasone—psoriasis	4.94e-05	0.000366	CcSEcCtD
Losartan—Oedema—Betamethasone—psoriasis	4.94e-05	0.000366	CcSEcCtD
Losartan—Oedema—Dexamethasone—psoriasis	4.94e-05	0.000366	CcSEcCtD
Losartan—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	4.93e-05	0.00138	CbGpPWpGaD
Losartan—Insomnia—Triamcinolone—psoriasis	4.92e-05	0.000365	CcSEcCtD
Losartan—Infection—Dexamethasone—psoriasis	4.91e-05	0.000364	CcSEcCtD
Losartan—Infection—Betamethasone—psoriasis	4.91e-05	0.000364	CcSEcCtD
Losartan—Ill-defined disorder—Prednisone—psoriasis	4.89e-05	0.000362	CcSEcCtD
Losartan—Paraesthesia—Triamcinolone—psoriasis	4.89e-05	0.000362	CcSEcCtD
Losartan—Feeling abnormal—Prednisolone—psoriasis	4.88e-05	0.000361	CcSEcCtD
Losartan—Anaemia—Prednisone—psoriasis	4.87e-05	0.000361	CcSEcCtD
Losartan—Shock—Dexamethasone—psoriasis	4.86e-05	0.00036	CcSEcCtD
Losartan—Shock—Betamethasone—psoriasis	4.86e-05	0.00036	CcSEcCtD
Losartan—Dyspnoea—Triamcinolone—psoriasis	4.85e-05	0.00036	CcSEcCtD
Losartan—Nervous system disorder—Dexamethasone—psoriasis	4.84e-05	0.000359	CcSEcCtD
Losartan—Nervous system disorder—Betamethasone—psoriasis	4.84e-05	0.000359	CcSEcCtD
Losartan—Agitation—Prednisone—psoriasis	4.84e-05	0.000359	CcSEcCtD
Losartan—Thrombocytopenia—Betamethasone—psoriasis	4.83e-05	0.000358	CcSEcCtD
Losartan—Thrombocytopenia—Dexamethasone—psoriasis	4.83e-05	0.000358	CcSEcCtD
Losartan—Tachycardia—Dexamethasone—psoriasis	4.82e-05	0.000357	CcSEcCtD
Losartan—Tachycardia—Betamethasone—psoriasis	4.82e-05	0.000357	CcSEcCtD
Losartan—Angioedema—Prednisone—psoriasis	4.81e-05	0.000357	CcSEcCtD
Losartan—Hypersensitivity—Cyclosporine—psoriasis	4.79e-05	0.000355	CcSEcCtD
Losartan—Dyspepsia—Triamcinolone—psoriasis	4.79e-05	0.000355	CcSEcCtD
Losartan—Erythema multiforme—Methotrexate—psoriasis	4.78e-05	0.000354	CcSEcCtD
Losartan—Nausea—Mycophenolic acid—psoriasis	4.77e-05	0.000354	CcSEcCtD
Losartan—Hyperhidrosis—Betamethasone—psoriasis	4.77e-05	0.000354	CcSEcCtD
Losartan—Hyperhidrosis—Dexamethasone—psoriasis	4.77e-05	0.000354	CcSEcCtD
Losartan—Feeling abnormal—Hydrocortisone—psoriasis	4.76e-05	0.000353	CcSEcCtD
Losartan—Malaise—Prednisone—psoriasis	4.75e-05	0.000352	CcSEcCtD
Losartan—Vertigo—Prednisone—psoriasis	4.73e-05	0.000351	CcSEcCtD
Losartan—Gastrointestinal pain—Hydrocortisone—psoriasis	4.73e-05	0.00035	CcSEcCtD
Losartan—Syncope—Prednisone—psoriasis	4.72e-05	0.00035	CcSEcCtD
Losartan—Tinnitus—Methotrexate—psoriasis	4.72e-05	0.000349	CcSEcCtD
Losartan—Anorexia—Dexamethasone—psoriasis	4.71e-05	0.000349	CcSEcCtD
Losartan—Anorexia—Betamethasone—psoriasis	4.71e-05	0.000349	CcSEcCtD
Losartan—SLCO1B3—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.7e-05	0.00131	CbGpPWpGaD
Losartan—Urticaria—Prednisolone—psoriasis	4.7e-05	0.000348	CcSEcCtD
Losartan—Fatigue—Triamcinolone—psoriasis	4.69e-05	0.000348	CcSEcCtD
Losartan—SLCO1B3—Transmembrane transport of small molecules—CP—psoriasis	4.69e-05	0.00131	CbGpPWpGaD
Losartan—Hypersensitivity—Mycophenolate mofetil—psoriasis	4.67e-05	0.000346	CcSEcCtD
Losartan—Asthenia—Cyclosporine—psoriasis	4.67e-05	0.000346	CcSEcCtD
Losartan—Pain—Triamcinolone—psoriasis	4.65e-05	0.000345	CcSEcCtD
Losartan—Loss of consciousness—Prednisone—psoriasis	4.63e-05	0.000343	CcSEcCtD
Losartan—Hypotension—Dexamethasone—psoriasis	4.61e-05	0.000342	CcSEcCtD
Losartan—Hypotension—Betamethasone—psoriasis	4.61e-05	0.000342	CcSEcCtD
Losartan—Pruritus—Cyclosporine—psoriasis	4.6e-05	0.000341	CcSEcCtD
Losartan—Urticaria—Hydrocortisone—psoriasis	4.59e-05	0.00034	CcSEcCtD
Losartan—Angiopathy—Methotrexate—psoriasis	4.59e-05	0.00034	CcSEcCtD
Losartan—Abdominal pain—Hydrocortisone—psoriasis	4.57e-05	0.000339	CcSEcCtD
Losartan—Body temperature increased—Hydrocortisone—psoriasis	4.57e-05	0.000339	CcSEcCtD
Losartan—UGT1A3—Metabolism—CYP2S1—psoriasis	4.55e-05	0.00127	CbGpPWpGaD
Losartan—UGT2B7—Metabolism—NDUFA5—psoriasis	4.55e-05	0.00127	CbGpPWpGaD
Losartan—Asthenia—Mycophenolate mofetil—psoriasis	4.55e-05	0.000337	CcSEcCtD
Losartan—AGTR1—Signaling Pathways—HCAR2—psoriasis	4.55e-05	0.00127	CbGpPWpGaD
Losartan—ALB—Folate Metabolism—ICAM1—psoriasis	4.54e-05	0.00127	CbGpPWpGaD
Losartan—Musculoskeletal discomfort—Dexamethasone—psoriasis	4.5e-05	0.000333	CcSEcCtD
Losartan—Musculoskeletal discomfort—Betamethasone—psoriasis	4.5e-05	0.000333	CcSEcCtD
Losartan—Pruritus—Mycophenolate mofetil—psoriasis	4.49e-05	0.000333	CcSEcCtD
Losartan—CYP3A4—Tryptophan metabolism—CAT—psoriasis	4.49e-05	0.00125	CbGpPWpGaD
Losartan—Arthralgia—Prednisone—psoriasis	4.49e-05	0.000332	CcSEcCtD
Losartan—Myalgia—Prednisone—psoriasis	4.49e-05	0.000332	CcSEcCtD
Losartan—Feeling abnormal—Triamcinolone—psoriasis	4.48e-05	0.000332	CcSEcCtD
Losartan—SLCO1B3—Transmembrane transport of small molecules—CARM1—psoriasis	4.47e-05	0.00125	CbGpPWpGaD
Losartan—Anxiety—Prednisone—psoriasis	4.47e-05	0.000331	CcSEcCtD
Losartan—Alopecia—Methotrexate—psoriasis	4.47e-05	0.000331	CcSEcCtD
Losartan—Insomnia—Betamethasone—psoriasis	4.47e-05	0.000331	CcSEcCtD
Losartan—Insomnia—Dexamethasone—psoriasis	4.47e-05	0.000331	CcSEcCtD
Losartan—ABCB1—Allograft Rejection—IL10—psoriasis	4.46e-05	0.00125	CbGpPWpGaD
Losartan—Diarrhoea—Cyclosporine—psoriasis	4.45e-05	0.00033	CcSEcCtD
Losartan—Paraesthesia—Dexamethasone—psoriasis	4.43e-05	0.000329	CcSEcCtD
Losartan—Paraesthesia—Betamethasone—psoriasis	4.43e-05	0.000329	CcSEcCtD
Losartan—Discomfort—Prednisone—psoriasis	4.43e-05	0.000328	CcSEcCtD
Losartan—Erythema—Methotrexate—psoriasis	4.4e-05	0.000326	CcSEcCtD
Losartan—AGTR1—GPCR downstream signaling—CCL20—psoriasis	4.4e-05	0.00123	CbGpPWpGaD
Losartan—Hypersensitivity—Prednisolone—psoriasis	4.36e-05	0.000323	CcSEcCtD
Losartan—Dyspepsia—Dexamethasone—psoriasis	4.35e-05	0.000322	CcSEcCtD
Losartan—Dyspepsia—Betamethasone—psoriasis	4.35e-05	0.000322	CcSEcCtD
Losartan—Diarrhoea—Mycophenolate mofetil—psoriasis	4.34e-05	0.000322	CcSEcCtD
Losartan—ABCB1—Allograft Rejection—IL4—psoriasis	4.34e-05	0.00121	CbGpPWpGaD
Losartan—Urticaria—Triamcinolone—psoriasis	4.32e-05	0.00032	CcSEcCtD
Losartan—UGT2B17—Metabolism—APOE—psoriasis	4.32e-05	0.00121	CbGpPWpGaD
Losartan—Dysgeusia—Methotrexate—psoriasis	4.31e-05	0.00032	CcSEcCtD
Losartan—Body temperature increased—Triamcinolone—psoriasis	4.3e-05	0.000319	CcSEcCtD
Losartan—Dizziness—Cyclosporine—psoriasis	4.3e-05	0.000319	CcSEcCtD
Losartan—Oedema—Prednisone—psoriasis	4.3e-05	0.000319	CcSEcCtD
Losartan—Anaphylactic shock—Prednisone—psoriasis	4.3e-05	0.000319	CcSEcCtD
Losartan—Decreased appetite—Dexamethasone—psoriasis	4.29e-05	0.000318	CcSEcCtD
Losartan—Decreased appetite—Betamethasone—psoriasis	4.29e-05	0.000318	CcSEcCtD
Losartan—SLCO1B3—Metabolism—CYP2S1—psoriasis	4.29e-05	0.0012	CbGpPWpGaD
Losartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	4.28e-05	0.0012	CbGpPWpGaD
Losartan—Infection—Prednisone—psoriasis	4.27e-05	0.000317	CcSEcCtD
Losartan—Back pain—Methotrexate—psoriasis	4.26e-05	0.000316	CcSEcCtD
Losartan—Hypersensitivity—Hydrocortisone—psoriasis	4.26e-05	0.000316	CcSEcCtD
Losartan—Fatigue—Dexamethasone—psoriasis	4.26e-05	0.000315	CcSEcCtD
Losartan—Fatigue—Betamethasone—psoriasis	4.26e-05	0.000315	CcSEcCtD
Losartan—ALB—Vitamin B12 Metabolism—IFNG—psoriasis	4.25e-05	0.00119	CbGpPWpGaD
Losartan—ABCB1—Allograft Rejection—HLA-B—psoriasis	4.24e-05	0.00118	CbGpPWpGaD
Losartan—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	4.24e-05	0.00118	CbGpPWpGaD
Losartan—Shock—Prednisone—psoriasis	4.23e-05	0.000314	CcSEcCtD
Losartan—Pain—Betamethasone—psoriasis	4.22e-05	0.000313	CcSEcCtD
Losartan—Pain—Dexamethasone—psoriasis	4.22e-05	0.000313	CcSEcCtD
Losartan—Nervous system disorder—Prednisone—psoriasis	4.22e-05	0.000313	CcSEcCtD
Losartan—Tachycardia—Prednisone—psoriasis	4.2e-05	0.000311	CcSEcCtD
Losartan—Dizziness—Mycophenolate mofetil—psoriasis	4.19e-05	0.000311	CcSEcCtD
Losartan—Hyperhidrosis—Prednisone—psoriasis	4.16e-05	0.000308	CcSEcCtD
Losartan—Vision blurred—Methotrexate—psoriasis	4.15e-05	0.000308	CcSEcCtD
Losartan—Asthenia—Hydrocortisone—psoriasis	4.15e-05	0.000307	CcSEcCtD
Losartan—Vomiting—Cyclosporine—psoriasis	4.13e-05	0.000306	CcSEcCtD
Losartan—AGTR1—Peptide ligand-binding receptors—CXCL8—psoriasis	4.12e-05	0.00115	CbGpPWpGaD
Losartan—Rash—Cyclosporine—psoriasis	4.1e-05	0.000304	CcSEcCtD
Losartan—Anorexia—Prednisone—psoriasis	4.1e-05	0.000304	CcSEcCtD
Losartan—Dermatitis—Cyclosporine—psoriasis	4.1e-05	0.000304	CcSEcCtD
Losartan—Pruritus—Hydrocortisone—psoriasis	4.09e-05	0.000303	CcSEcCtD
Losartan—Ill-defined disorder—Methotrexate—psoriasis	4.09e-05	0.000303	CcSEcCtD
Losartan—Headache—Cyclosporine—psoriasis	4.07e-05	0.000302	CcSEcCtD
Losartan—Anaemia—Methotrexate—psoriasis	4.07e-05	0.000302	CcSEcCtD
Losartan—Feeling abnormal—Dexamethasone—psoriasis	4.07e-05	0.000302	CcSEcCtD
Losartan—Feeling abnormal—Betamethasone—psoriasis	4.07e-05	0.000302	CcSEcCtD
Losartan—Gastrointestinal pain—Dexamethasone—psoriasis	4.04e-05	0.000299	CcSEcCtD
Losartan—Gastrointestinal pain—Betamethasone—psoriasis	4.04e-05	0.000299	CcSEcCtD
Losartan—Vomiting—Mycophenolate mofetil—psoriasis	4.03e-05	0.000299	CcSEcCtD
Losartan—Hypersensitivity—Triamcinolone—psoriasis	4.01e-05	0.000297	CcSEcCtD
Losartan—Rash—Mycophenolate mofetil—psoriasis	4e-05	0.000296	CcSEcCtD
Losartan—AGTR1—Signaling by GPCR—CCL20—psoriasis	4e-05	0.00112	CbGpPWpGaD
Losartan—Dermatitis—Mycophenolate mofetil—psoriasis	4e-05	0.000296	CcSEcCtD
Losartan—Headache—Mycophenolate mofetil—psoriasis	3.97e-05	0.000295	CcSEcCtD
Losartan—Malaise—Methotrexate—psoriasis	3.97e-05	0.000294	CcSEcCtD
Losartan—Vertigo—Methotrexate—psoriasis	3.96e-05	0.000293	CcSEcCtD
Losartan—Diarrhoea—Hydrocortisone—psoriasis	3.95e-05	0.000293	CcSEcCtD
Losartan—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	3.95e-05	0.0011	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—TAGAP—psoriasis	3.94e-05	0.0011	CbGpPWpGaD
Losartan—Leukopenia—Methotrexate—psoriasis	3.94e-05	0.000292	CcSEcCtD
Losartan—ABCB1—Allograft Rejection—HLA-A—psoriasis	3.93e-05	0.0011	CbGpPWpGaD
Losartan—ALB—Selenium Micronutrient Network—CRP—psoriasis	3.93e-05	0.0011	CbGpPWpGaD
Losartan—Urticaria—Dexamethasone—psoriasis	3.92e-05	0.000291	CcSEcCtD
Losartan—Urticaria—Betamethasone—psoriasis	3.92e-05	0.000291	CcSEcCtD
Losartan—Musculoskeletal discomfort—Prednisone—psoriasis	3.92e-05	0.00029	CcSEcCtD
Losartan—Dizziness—Prednisolone—psoriasis	3.91e-05	0.00029	CcSEcCtD
Losartan—Asthenia—Triamcinolone—psoriasis	3.9e-05	0.000289	CcSEcCtD
Losartan—Abdominal pain—Betamethasone—psoriasis	3.9e-05	0.000289	CcSEcCtD
Losartan—Body temperature increased—Betamethasone—psoriasis	3.9e-05	0.000289	CcSEcCtD
Losartan—Body temperature increased—Dexamethasone—psoriasis	3.9e-05	0.000289	CcSEcCtD
Losartan—Abdominal pain—Dexamethasone—psoriasis	3.9e-05	0.000289	CcSEcCtD
Losartan—Insomnia—Prednisone—psoriasis	3.89e-05	0.000288	CcSEcCtD
Losartan—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	3.88e-05	0.00108	CbGpPWpGaD
Losartan—UGT2B7—Metabolism—CYP2S1—psoriasis	3.87e-05	0.00108	CbGpPWpGaD
Losartan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	3.87e-05	0.00108	CbGpPWpGaD
Losartan—Nausea—Cyclosporine—psoriasis	3.86e-05	0.000286	CcSEcCtD
Losartan—Paraesthesia—Prednisone—psoriasis	3.86e-05	0.000286	CcSEcCtD
Losartan—Pruritus—Triamcinolone—psoriasis	3.85e-05	0.000285	CcSEcCtD
Losartan—Cough—Methotrexate—psoriasis	3.84e-05	0.000285	CcSEcCtD
Losartan—Dizziness—Hydrocortisone—psoriasis	3.82e-05	0.000283	CcSEcCtD
Losartan—Dyspepsia—Prednisone—psoriasis	3.78e-05	0.000281	CcSEcCtD
Losartan—Nausea—Mycophenolate mofetil—psoriasis	3.77e-05	0.000279	CcSEcCtD
Losartan—UGT2B17—Metabolism—PPARG—psoriasis	3.76e-05	0.00105	CbGpPWpGaD
Losartan—Chest pain—Methotrexate—psoriasis	3.75e-05	0.000278	CcSEcCtD
Losartan—Myalgia—Methotrexate—psoriasis	3.75e-05	0.000278	CcSEcCtD
Losartan—Arthralgia—Methotrexate—psoriasis	3.75e-05	0.000278	CcSEcCtD
Losartan—Decreased appetite—Prednisone—psoriasis	3.74e-05	0.000277	CcSEcCtD
Losartan—Rash—Prednisolone—psoriasis	3.73e-05	0.000276	CcSEcCtD
Losartan—Dermatitis—Prednisolone—psoriasis	3.73e-05	0.000276	CcSEcCtD
Losartan—Fatigue—Prednisone—psoriasis	3.71e-05	0.000275	CcSEcCtD
Losartan—Headache—Prednisolone—psoriasis	3.71e-05	0.000275	CcSEcCtD
Losartan—Discomfort—Methotrexate—psoriasis	3.7e-05	0.000274	CcSEcCtD
Losartan—UGT1A1—Metabolism—NDUFA5—psoriasis	3.7e-05	0.00103	CbGpPWpGaD
Losartan—Constipation—Prednisone—psoriasis	3.68e-05	0.000273	CcSEcCtD
Losartan—Vomiting—Hydrocortisone—psoriasis	3.67e-05	0.000272	CcSEcCtD
Losartan—Rash—Hydrocortisone—psoriasis	3.64e-05	0.00027	CcSEcCtD
Losartan—Dermatitis—Hydrocortisone—psoriasis	3.64e-05	0.00027	CcSEcCtD
Losartan—Confusional state—Methotrexate—psoriasis	3.62e-05	0.000269	CcSEcCtD
Losartan—Headache—Hydrocortisone—psoriasis	3.62e-05	0.000268	CcSEcCtD
Losartan—ALB—Selenium Micronutrient Network—ICAM1—psoriasis	3.61e-05	0.00101	CbGpPWpGaD
Losartan—Dizziness—Triamcinolone—psoriasis	3.6e-05	0.000267	CcSEcCtD
Losartan—Anaphylactic shock—Methotrexate—psoriasis	3.59e-05	0.000266	CcSEcCtD
Losartan—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	3.59e-05	0.001	CbGpPWpGaD
Losartan—Infection—Methotrexate—psoriasis	3.57e-05	0.000265	CcSEcCtD
Losartan—Feeling abnormal—Prednisone—psoriasis	3.54e-05	0.000263	CcSEcCtD
Losartan—ALB—SLC-mediated transmembrane transport—CP—psoriasis	3.54e-05	0.000989	CbGpPWpGaD
Losartan—Asthenia—Betamethasone—psoriasis	3.54e-05	0.000263	CcSEcCtD
Losartan—Asthenia—Dexamethasone—psoriasis	3.54e-05	0.000263	CcSEcCtD
Losartan—ALB—Vitamin B12 Metabolism—NFKB1—psoriasis	3.54e-05	0.000987	CbGpPWpGaD
Losartan—Nervous system disorder—Methotrexate—psoriasis	3.52e-05	0.000261	CcSEcCtD
Losartan—Thrombocytopenia—Methotrexate—psoriasis	3.52e-05	0.000261	CcSEcCtD
Losartan—Gastrointestinal pain—Prednisone—psoriasis	3.52e-05	0.000261	CcSEcCtD
Losartan—Nausea—Prednisolone—psoriasis	3.51e-05	0.00026	CcSEcCtD
Losartan—Pruritus—Dexamethasone—psoriasis	3.49e-05	0.000259	CcSEcCtD
Losartan—Pruritus—Betamethasone—psoriasis	3.49e-05	0.000259	CcSEcCtD
Losartan—Hyperhidrosis—Methotrexate—psoriasis	3.47e-05	0.000257	CcSEcCtD
Losartan—SLC22A6—Transmembrane transport of small molecules—CP—psoriasis	3.46e-05	0.000967	CbGpPWpGaD
Losartan—Vomiting—Triamcinolone—psoriasis	3.46e-05	0.000256	CcSEcCtD
Losartan—ALB—Folate Metabolism—IFNG—psoriasis	3.46e-05	0.000965	CbGpPWpGaD
Losartan—Nausea—Hydrocortisone—psoriasis	3.43e-05	0.000254	CcSEcCtD
Losartan—Rash—Triamcinolone—psoriasis	3.43e-05	0.000254	CcSEcCtD
Losartan—Dermatitis—Triamcinolone—psoriasis	3.43e-05	0.000254	CcSEcCtD
Losartan—Anorexia—Methotrexate—psoriasis	3.43e-05	0.000254	CcSEcCtD
Losartan—Urticaria—Prednisone—psoriasis	3.42e-05	0.000253	CcSEcCtD
Losartan—Headache—Triamcinolone—psoriasis	3.41e-05	0.000253	CcSEcCtD
Losartan—Abdominal pain—Prednisone—psoriasis	3.4e-05	0.000252	CcSEcCtD
Losartan—Body temperature increased—Prednisone—psoriasis	3.4e-05	0.000252	CcSEcCtD
Losartan—SLCO1B1—Metabolism—NDUFA5—psoriasis	3.39e-05	0.000946	CbGpPWpGaD
Losartan—Diarrhoea—Dexamethasone—psoriasis	3.38e-05	0.00025	CcSEcCtD
Losartan—Diarrhoea—Betamethasone—psoriasis	3.38e-05	0.00025	CcSEcCtD
Losartan—Hypotension—Methotrexate—psoriasis	3.36e-05	0.000249	CcSEcCtD
Losartan—ACE—Metabolism of proteins—LEP—psoriasis	3.34e-05	0.000932	CbGpPWpGaD
Losartan—SLC22A6—Transmembrane transport of small molecules—CARM1—psoriasis	3.3e-05	0.000922	CbGpPWpGaD
Losartan—Musculoskeletal discomfort—Methotrexate—psoriasis	3.27e-05	0.000243	CcSEcCtD
Losartan—Dizziness—Betamethasone—psoriasis	3.26e-05	0.000242	CcSEcCtD
Losartan—Dizziness—Dexamethasone—psoriasis	3.26e-05	0.000242	CcSEcCtD
Losartan—Insomnia—Methotrexate—psoriasis	3.25e-05	0.000241	CcSEcCtD
Losartan—Nausea—Triamcinolone—psoriasis	3.23e-05	0.00024	CcSEcCtD
Losartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	3.23e-05	0.000901	CbGpPWpGaD
Losartan—Paraesthesia—Methotrexate—psoriasis	3.23e-05	0.000239	CcSEcCtD
Losartan—Dyspnoea—Methotrexate—psoriasis	3.2e-05	0.000237	CcSEcCtD
Losartan—Somnolence—Methotrexate—psoriasis	3.19e-05	0.000237	CcSEcCtD
Losartan—Hypersensitivity—Prednisone—psoriasis	3.17e-05	0.000235	CcSEcCtD
Losartan—Dyspepsia—Methotrexate—psoriasis	3.16e-05	0.000234	CcSEcCtD
Losartan—SLCO1B1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.16e-05	0.000882	CbGpPWpGaD
Losartan—SLCO1B1—Transmembrane transport of small molecules—CP—psoriasis	3.15e-05	0.000879	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—CYP2S1—psoriasis	3.15e-05	0.000878	CbGpPWpGaD
Losartan—Vomiting—Dexamethasone—psoriasis	3.14e-05	0.000233	CcSEcCtD
Losartan—Vomiting—Betamethasone—psoriasis	3.14e-05	0.000233	CcSEcCtD
Losartan—Decreased appetite—Methotrexate—psoriasis	3.12e-05	0.000232	CcSEcCtD
Losartan—Rash—Dexamethasone—psoriasis	3.11e-05	0.000231	CcSEcCtD
Losartan—Rash—Betamethasone—psoriasis	3.11e-05	0.000231	CcSEcCtD
Losartan—Dermatitis—Dexamethasone—psoriasis	3.11e-05	0.000231	CcSEcCtD
Losartan—Dermatitis—Betamethasone—psoriasis	3.11e-05	0.000231	CcSEcCtD
Losartan—Fatigue—Methotrexate—psoriasis	3.1e-05	0.00023	CcSEcCtD
Losartan—Headache—Dexamethasone—psoriasis	3.09e-05	0.000229	CcSEcCtD
Losartan—Headache—Betamethasone—psoriasis	3.09e-05	0.000229	CcSEcCtD
Losartan—Asthenia—Prednisone—psoriasis	3.08e-05	0.000229	CcSEcCtD
Losartan—Pain—Methotrexate—psoriasis	3.07e-05	0.000228	CcSEcCtD
Losartan—Pruritus—Prednisone—psoriasis	3.04e-05	0.000225	CcSEcCtD
Losartan—SLCO1B1—Transmembrane transport of small molecules—CARM1—psoriasis	3.01e-05	0.000839	CbGpPWpGaD
Losartan—Feeling abnormal—Methotrexate—psoriasis	2.96e-05	0.000219	CcSEcCtD
Losartan—Diarrhoea—Prednisone—psoriasis	2.94e-05	0.000218	CcSEcCtD
Losartan—Gastrointestinal pain—Methotrexate—psoriasis	2.94e-05	0.000218	CcSEcCtD
Losartan—Nausea—Dexamethasone—psoriasis	2.93e-05	0.000217	CcSEcCtD
Losartan—Nausea—Betamethasone—psoriasis	2.93e-05	0.000217	CcSEcCtD
Losartan—SLCO1B1—Metabolism—CYP2S1—psoriasis	2.88e-05	0.000805	CbGpPWpGaD
Losartan—ALB—Folate Metabolism—NFKB1—psoriasis	2.88e-05	0.000803	CbGpPWpGaD
Losartan—Urticaria—Methotrexate—psoriasis	2.85e-05	0.000212	CcSEcCtD
Losartan—Dizziness—Prednisone—psoriasis	2.84e-05	0.000211	CcSEcCtD
Losartan—Body temperature increased—Methotrexate—psoriasis	2.84e-05	0.000211	CcSEcCtD
Losartan—Abdominal pain—Methotrexate—psoriasis	2.84e-05	0.000211	CcSEcCtD
Losartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	2.79e-05	0.000779	CbGpPWpGaD
Losartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.76e-05	0.000771	CbGpPWpGaD
Losartan—ALB—Vitamin B12 Metabolism—TNF—psoriasis	2.75e-05	0.000768	CbGpPWpGaD
Losartan—ALB—Selenium Micronutrient Network—IFNG—psoriasis	2.75e-05	0.000767	CbGpPWpGaD
Losartan—Vomiting—Prednisone—psoriasis	2.73e-05	0.000203	CcSEcCtD
Losartan—Rash—Prednisone—psoriasis	2.71e-05	0.000201	CcSEcCtD
Losartan—Dermatitis—Prednisone—psoriasis	2.71e-05	0.000201	CcSEcCtD
Losartan—Headache—Prednisone—psoriasis	2.69e-05	0.0002	CcSEcCtD
Losartan—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	2.69e-05	0.00075	CbGpPWpGaD
Losartan—Hypersensitivity—Methotrexate—psoriasis	2.65e-05	0.000196	CcSEcCtD
Losartan—ABCB1—Allograft Rejection—IFNG—psoriasis	2.62e-05	0.000732	CbGpPWpGaD
Losartan—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	2.62e-05	0.000731	CbGpPWpGaD
Losartan—Asthenia—Methotrexate—psoriasis	2.58e-05	0.000191	CcSEcCtD
Losartan—Nausea—Prednisone—psoriasis	2.55e-05	0.000189	CcSEcCtD
Losartan—Pruritus—Methotrexate—psoriasis	2.54e-05	0.000188	CcSEcCtD
Losartan—Diarrhoea—Methotrexate—psoriasis	2.46e-05	0.000182	CcSEcCtD
Losartan—ABCB1—Allograft Rejection—CXCL8—psoriasis	2.44e-05	0.000681	CbGpPWpGaD
Losartan—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	2.44e-05	0.00068	CbGpPWpGaD
Losartan—Dizziness—Methotrexate—psoriasis	2.38e-05	0.000176	CcSEcCtD
Losartan—AGTR1—Signaling Pathways—CCL20—psoriasis	2.36e-05	0.000659	CbGpPWpGaD
Losartan—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	2.29e-05	0.000638	CbGpPWpGaD
Losartan—ALB—Selenium Micronutrient Network—NFKB1—psoriasis	2.29e-05	0.000638	CbGpPWpGaD
Losartan—Vomiting—Methotrexate—psoriasis	2.28e-05	0.000169	CcSEcCtD
Losartan—Rash—Methotrexate—psoriasis	2.27e-05	0.000168	CcSEcCtD
Losartan—Dermatitis—Methotrexate—psoriasis	2.26e-05	0.000168	CcSEcCtD
Losartan—Headache—Methotrexate—psoriasis	2.25e-05	0.000167	CcSEcCtD
Losartan—CYP3A5—Metabolism—NDUFA5—psoriasis	2.25e-05	0.000628	CbGpPWpGaD
Losartan—SLCO1B3—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.25e-05	0.000628	CbGpPWpGaD
Losartan—ALB—Platelet degranulation—VEGFA—psoriasis	2.24e-05	0.000625	CbGpPWpGaD
Losartan—ALB—Folate Metabolism—TNF—psoriasis	2.24e-05	0.000625	CbGpPWpGaD
Losartan—UGT1A3—Metabolism—CARM1—psoriasis	2.22e-05	0.000621	CbGpPWpGaD
Losartan—ALB—Vitamin B12 Metabolism—IL6—psoriasis	2.22e-05	0.000619	CbGpPWpGaD
Losartan—ACE—Metabolism of proteins—CXCL8—psoriasis	2.22e-05	0.000619	CbGpPWpGaD
Losartan—ALB—Hemostasis—ITGAL—psoriasis	2.15e-05	0.000601	CbGpPWpGaD
Losartan—Nausea—Methotrexate—psoriasis	2.13e-05	0.000158	CcSEcCtD
Losartan—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	2.13e-05	0.000595	CbGpPWpGaD
Losartan—AGTR1—GPCR ligand binding—CXCL8—psoriasis	2.1e-05	0.000587	CbGpPWpGaD
Losartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	2.1e-05	0.000585	CbGpPWpGaD
Losartan—SLCO1B3—Metabolism—CARM1—psoriasis	2.1e-05	0.000585	CbGpPWpGaD
Losartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	2.09e-05	0.000583	CbGpPWpGaD
Losartan—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	2.09e-05	0.000583	CbGpPWpGaD
Losartan—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	2.01e-05	0.000561	CbGpPWpGaD
Losartan—ABCB1—Allograft Rejection—VEGFA—psoriasis	1.98e-05	0.000553	CbGpPWpGaD
Losartan—ALB—Folate Metabolism—TP53—psoriasis	1.97e-05	0.000551	CbGpPWpGaD
Losartan—SLCO1B3—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.96e-05	0.000547	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—NDUFA5—psoriasis	1.95e-05	0.000544	CbGpPWpGaD
Losartan—ALB—Metabolism—NDUFA5—psoriasis	1.94e-05	0.000541	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—CYP2S1—psoriasis	1.91e-05	0.000534	CbGpPWpGaD
Losartan—UGT2B7—Metabolism—CARM1—psoriasis	1.89e-05	0.000528	CbGpPWpGaD
Losartan—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.82e-05	0.000507	CbGpPWpGaD
Losartan—ALB—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.81e-05	0.000504	CbGpPWpGaD
Losartan—ALB—Folate Metabolism—IL6—psoriasis	1.81e-05	0.000504	CbGpPWpGaD
Losartan—ALB—Transmembrane transport of small molecules—CP—psoriasis	1.8e-05	0.000502	CbGpPWpGaD
Losartan—ALB—Selenium Micronutrient Network—TNF—psoriasis	1.78e-05	0.000496	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—NDUFA5—psoriasis	1.74e-05	0.000485	CbGpPWpGaD
Losartan—ALB—Transmembrane transport of small molecules—CARM1—psoriasis	1.72e-05	0.000479	CbGpPWpGaD
Losartan—ABCB1—Allograft Rejection—TNF—psoriasis	1.7e-05	0.000474	CbGpPWpGaD
Losartan—ABCB1—Metabolism—NDUFA5—psoriasis	1.7e-05	0.000474	CbGpPWpGaD
Losartan—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	1.69e-05	0.000471	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—CYP2S1—psoriasis	1.66e-05	0.000462	CbGpPWpGaD
Losartan—ALB—Metabolism—CYP2S1—psoriasis	1.65e-05	0.00046	CbGpPWpGaD
Losartan—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.62e-05	0.000453	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—NDUFA5—psoriasis	1.59e-05	0.000443	CbGpPWpGaD
Losartan—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	1.58e-05	0.00044	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—CARM1—psoriasis	1.54e-05	0.000429	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.51e-05	0.000422	CbGpPWpGaD
Losartan—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	1.5e-05	0.00042	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—CYP2S1—psoriasis	1.48e-05	0.000413	CbGpPWpGaD
Losartan—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.48e-05	0.000413	CbGpPWpGaD
Losartan—ABCB1—Metabolism—CYP2S1—psoriasis	1.44e-05	0.000403	CbGpPWpGaD
Losartan—ALB—Selenium Micronutrient Network—IL6—psoriasis	1.43e-05	0.0004	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—CARM1—psoriasis	1.41e-05	0.000393	CbGpPWpGaD
Losartan—UGT1A3—Metabolism—CAT—psoriasis	1.37e-05	0.000382	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—NDUFA5—psoriasis	1.35e-05	0.000378	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—CYP2S1—psoriasis	1.35e-05	0.000376	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.32e-05	0.000367	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—SOCS1—psoriasis	1.3e-05	0.000363	CbGpPWpGaD
Losartan—SLCO1B3—Metabolism—CAT—psoriasis	1.29e-05	0.00036	CbGpPWpGaD
Losartan—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.26e-05	0.000353	CbGpPWpGaD
Losartan—AGTR1—Signaling by GPCR—TYK2—psoriasis	1.24e-05	0.000346	CbGpPWpGaD
Losartan—AGTR1—GPCR downstream signaling—CXCL8—psoriasis	1.19e-05	0.000332	CbGpPWpGaD
Losartan—UGT2B7—Metabolism—CAT—psoriasis	1.16e-05	0.000325	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—CYP2S1—psoriasis	1.15e-05	0.000322	CbGpPWpGaD
Losartan—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.12e-05	0.000312	CbGpPWpGaD
Losartan—AGTR1—Signaling by GPCR—CXCL8—psoriasis	1.08e-05	0.000301	CbGpPWpGaD
Losartan—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.08e-05	0.000301	CbGpPWpGaD
Losartan—UGT1A3—Metabolism—APOE—psoriasis	1.06e-05	0.000297	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—NDUFA5—psoriasis	1.05e-05	0.000292	CbGpPWpGaD
Losartan—SLCO1B3—Metabolism—APOE—psoriasis	1e-05	0.00028	CbGpPWpGaD
Losartan—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	9.93e-06	0.000277	CbGpPWpGaD
Losartan—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	9.78e-06	0.000273	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—LEP—psoriasis	9.6e-06	0.000268	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—APOE—psoriasis	9.6e-06	0.000268	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—CAT—psoriasis	9.45e-06	0.000264	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—CARM1—psoriasis	9.34e-06	0.000261	CbGpPWpGaD
Losartan—UGT1A3—Metabolism—PPARG—psoriasis	9.26e-06	0.000258	CbGpPWpGaD
Losartan—UGT2B7—Metabolism—APOE—psoriasis	9.04e-06	0.000252	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—NFKBIA—psoriasis	8.94e-06	0.00025	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—CYP2S1—psoriasis	8.89e-06	0.000248	CbGpPWpGaD
Losartan—ALB—Hemostasis—NOS2—psoriasis	8.84e-06	0.000247	CbGpPWpGaD
Losartan—SLCO1B3—Metabolism—PPARG—psoriasis	8.72e-06	0.000243	CbGpPWpGaD
Losartan—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.68e-06	0.000242	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—CAT—psoriasis	8.66e-06	0.000242	CbGpPWpGaD
Losartan—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.63e-06	0.000241	CbGpPWpGaD
Losartan—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	8.38e-06	0.000234	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—CARM1—psoriasis	8.09e-06	0.000226	CbGpPWpGaD
Losartan—ALB—Metabolism—CARM1—psoriasis	8.04e-06	0.000225	CbGpPWpGaD
Losartan—UGT2B7—Metabolism—PPARG—psoriasis	7.87e-06	0.00022	CbGpPWpGaD
Losartan—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.75e-06	0.000216	CbGpPWpGaD
Losartan—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.56e-06	0.000211	CbGpPWpGaD
Losartan—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.52e-06	0.00021	CbGpPWpGaD
Losartan—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	7.39e-06	0.000206	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—APOE—psoriasis	7.34e-06	0.000205	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—TYK2—psoriasis	7.32e-06	0.000204	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—CARM1—psoriasis	7.22e-06	0.000202	CbGpPWpGaD
Losartan—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.07e-06	0.000197	CbGpPWpGaD
Losartan—ABCB1—Metabolism—CARM1—psoriasis	7.05e-06	0.000197	CbGpPWpGaD
Losartan—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.75e-06	0.000188	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—APOE—psoriasis	6.73e-06	0.000188	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—CARM1—psoriasis	6.58e-06	0.000184	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—PPARG—psoriasis	6.4e-06	0.000179	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—CXCL8—psoriasis	6.38e-06	0.000178	CbGpPWpGaD
Losartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.15e-06	0.000172	CbGpPWpGaD
Losartan—AGTR1—Signaling by GPCR—IL6—psoriasis	6.06e-06	0.000169	CbGpPWpGaD
Losartan—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.04e-06	0.000169	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—JUN—psoriasis	5.93e-06	0.000165	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—PPARG—psoriasis	5.86e-06	0.000164	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—CAT—psoriasis	5.74e-06	0.00016	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—NFKB1—psoriasis	5.71e-06	0.000159	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—CARM1—psoriasis	5.63e-06	0.000157	CbGpPWpGaD
Losartan—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.26e-06	0.000147	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—VEGFA—psoriasis	5.18e-06	0.000145	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—STAT3—psoriasis	5.13e-06	0.000143	CbGpPWpGaD
Losartan—ALB—Hemostasis—VEGFA—psoriasis	5.12e-06	0.000143	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—CAT—psoriasis	4.98e-06	0.000139	CbGpPWpGaD
Losartan—ALB—Metabolism—CAT—psoriasis	4.95e-06	0.000138	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—APOE—psoriasis	4.46e-06	0.000125	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—CAT—psoriasis	4.44e-06	0.000124	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—CARM1—psoriasis	4.34e-06	0.000121	CbGpPWpGaD
Losartan—ABCB1—Metabolism—CAT—psoriasis	4.33e-06	0.000121	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—CAT—psoriasis	4.05e-06	0.000113	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—TP53—psoriasis	3.91e-06	0.000109	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—PPARG—psoriasis	3.89e-06	0.000109	CbGpPWpGaD
Losartan—ALB—Hemostasis—TP53—psoriasis	3.87e-06	0.000108	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—APOE—psoriasis	3.87e-06	0.000108	CbGpPWpGaD
Losartan—ALB—Metabolism—APOE—psoriasis	3.84e-06	0.000107	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—IL6—psoriasis	3.58e-06	0.0001	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—CAT—psoriasis	3.46e-06	9.66e-05	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—APOE—psoriasis	3.45e-06	9.63e-05	CbGpPWpGaD
Losartan—ABCB1—Metabolism—APOE—psoriasis	3.37e-06	9.4e-05	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—PPARG—psoriasis	3.37e-06	9.4e-05	CbGpPWpGaD
Losartan—ALB—Metabolism—PPARG—psoriasis	3.35e-06	9.35e-05	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—APOE—psoriasis	3.15e-06	8.78e-05	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—PPARG—psoriasis	3.01e-06	8.39e-05	CbGpPWpGaD
Losartan—ABCB1—Metabolism—PPARG—psoriasis	2.93e-06	8.19e-05	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—PPARG—psoriasis	2.74e-06	7.65e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—APOE—psoriasis	2.69e-06	7.51e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—CAT—psoriasis	2.67e-06	7.45e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—PPARG—psoriasis	2.34e-06	6.54e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—APOE—psoriasis	2.08e-06	5.79e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—PPARG—psoriasis	1.81e-06	5.05e-05	CbGpPWpGaD
